BridgeBio Pharma Inc vs Nerdwallet Inc — how do they compare? BridgeBio Pharma Inc trades at $83.9 (market cap $16.61B), while Nerdwallet Inc trades at $9.78 (market cap $627.09M). The key difference: BridgeBio Pharma Inc is far larger — about 26.5× Nerdwallet Inc's market cap, and BridgeBio Pharma Inc is trading nearer its 52-week high, Nerdwallet Inc nearer its low. Which is the better fit depends on your goals.
| BBIO | NRDS | |
|---|---|---|
Market Cap | $16.61B | $627.09M |
Sector | Health | Financials |
52-Week High | $90.17 | $15.93 |
52-Week Low | $47.29 | $7.58 |
Enterprise Value | $18.16B | $541.39M |
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $84.48, up 2.03% with bullish technical signals from moving averages. Despite strong revenue growth from $222M in 2024 to $502M in 2025, the company reports significant losses with a -144.39% net margin. Recent FDA acceptance for encaleret in ADH1 and Attruby's commercial expansion in ATTR-CM provide growth catalysts, though cash flow remains negative at -$111M in 2025.
The stock presents high-risk growth potential with 88% analyst buy ratings and $102.20 consensus target, but faces substantial execution risks from ongoing losses and $1.72B debt load. Success hinges on pipeline approvals and Attruby's market penetration, making it suitable for risk-tolerant investors betting on biotech breakthroughs.
NerdWallet (NRDS) trades at $9.91, up 12.1% in the past 24 hours, with a bullish technical signal from moving averages. The company shows strong revenue growth from $539M in 2022 to $837M in 2025, with net income turning positive to $48.7M. Recent Q2 2026 earnings missed expectations at $0.07 per share versus $0.0934 expected, though Q1 and Q4 2025 beat estimates. Valuation metrics appear attractive with a P/E of 10.9 and P/S of 0.82.
The outlook remains positive with analyst consensus favoring Buy ratings (66.7%) and projected 27.9% upside potential. Key risks include execution challenges in shifting from SEO-dependent referrals and competitive pressure in financial guidance markets. Strong cash flow generation and improving profitability support the bullish case, though investors should monitor quarterly earnings consistency.
Trailing returns across standard periods
Latest headlines on both assets
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →Nerdwallet Inc is a free tool to find you the best credit cards, cd rates, savings, checking accounts, scholarships, healthcare and airlines.
Read more on NRDS →